Vident Investment Advisory LLC increased its position in AstraZeneca plc (NYSE:AZN) by 10.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 37,505 shares of the company’s stock after purchasing an additional 3,522 shares during the period. Vident Investment Advisory LLC’s holdings in AstraZeneca were worth $1,301,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its position in AstraZeneca by 9.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,713 shares of the company’s stock valued at $502,000 after purchasing an additional 1,327 shares during the period. Commerce Bank boosted its holdings in shares of AstraZeneca by 14.7% during the 4th quarter. Commerce Bank now owns 11,548 shares of the company’s stock valued at $400,000 after buying an additional 1,480 shares in the last quarter. M&T Bank Corp boosted its holdings in shares of AstraZeneca by 0.5% during the 4th quarter. M&T Bank Corp now owns 317,119 shares of the company’s stock valued at $11,003,000 after buying an additional 1,676 shares in the last quarter. TIAA FSB boosted its holdings in shares of AstraZeneca by 6.7% during the 4th quarter. TIAA FSB now owns 27,087 shares of the company’s stock valued at $940,000 after buying an additional 1,692 shares in the last quarter. Finally, First Allied Advisory Services Inc. boosted its holdings in shares of AstraZeneca by 7.6% during the 4th quarter. First Allied Advisory Services Inc. now owns 23,845 shares of the company’s stock valued at $825,000 after buying an additional 1,694 shares in the last quarter. 15.13% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

A number of analysts have recently commented on AZN shares. JPMorgan Chase & Co. upgraded shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a report on Friday, December 29th. Zacks Investment Research cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the company a “buy” rating in a report on Wednesday, January 10th. Leerink Swann restated a “market perform” rating and set a $36.00 target price (up previously from $33.00) on shares of AstraZeneca in a report on Thursday, January 18th. Finally, ValuEngine upgraded shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 3rd. Three analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. AstraZeneca presently has an average rating of “Hold” and a consensus price target of $36.32.

Shares of AstraZeneca stock opened at $34.61 on Thursday. AstraZeneca plc has a 52-week low of $28.43 and a 52-week high of $36.70. The company has a market cap of $88,068.80, a PE ratio of 14.60, a PEG ratio of 2.07 and a beta of 0.71. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.62 and a current ratio of 0.80.

AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Friday, February 2nd. The company reported $1.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.86. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The firm had revenue of $5.78 billion during the quarter, compared to analyst estimates of $5.49 billion. During the same quarter in the prior year, the firm earned $1.21 EPS. The business’s revenue for the quarter was up 3.4% compared to the same quarter last year. sell-side analysts expect that AstraZeneca plc will post 1.7 earnings per share for the current fiscal year.

The company also recently announced a semiannual dividend, which was paid on Monday, March 19th. Investors of record on Friday, February 16th were issued a $0.95 dividend. This represents a yield of 5.62%. The ex-dividend date was Thursday, February 15th. AstraZeneca’s dividend payout ratio is 57.81%.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/vident-investment-advisory-llc-has-1-30-million-position-in-astrazeneca-plc-azn/1957399.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.